ES2062061T3 - Compuestos radiohalogenados para el marcaje especifico de sitio. - Google Patents

Compuestos radiohalogenados para el marcaje especifico de sitio.

Info

Publication number
ES2062061T3
ES2062061T3 ES89401557T ES89401557T ES2062061T3 ES 2062061 T3 ES2062061 T3 ES 2062061T3 ES 89401557 T ES89401557 T ES 89401557T ES 89401557 T ES89401557 T ES 89401557T ES 2062061 T3 ES2062061 T3 ES 2062061T3
Authority
ES
Spain
Prior art keywords
radiohalogenated
compounds
specific site
site marking
radiohalogenated compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89401557T
Other languages
English (en)
Inventor
Daniel James Coughlin
Benjamin A Belinka
Vernon Leon Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of ES2062061T3 publication Critical patent/ES2062061T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTO RADIOHALOGENADOS QUE SON UTILES COMO COMPUESTOS INTERMEDIOS PARA PREPARAR CONJUGADOS DE ANTICUERPOS RADIOHALOGENADOS EN LOS QUE EL COMPUESTO RADIOHALOGENADO ESTA UNIDO ESPECIFICAMENTE POR UN PUNTO A UNA PORCION O UN FRAGMENTO DE ANTICUERPO. TAMBIEN INCLUYE LA INVENCION METODOS PARA LA PREPARACION DE LOS COMPUESTOS Y LOS CONJUGADOS DEL ANTICUERPO ASI COMO METODOS PARA SU EMPLEO.
ES89401557T 1988-06-07 1989-06-06 Compuestos radiohalogenados para el marcaje especifico de sitio. Expired - Lifetime ES2062061T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/203,793 US4966999A (en) 1988-06-07 1988-06-07 Radiohalogenated compounds for site specific labeling

Publications (1)

Publication Number Publication Date
ES2062061T3 true ES2062061T3 (es) 1994-12-16

Family

ID=22755342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89401557T Expired - Lifetime ES2062061T3 (es) 1988-06-07 1989-06-06 Compuestos radiohalogenados para el marcaje especifico de sitio.

Country Status (9)

Country Link
US (1) US4966999A (es)
EP (1) EP0348261B1 (es)
JP (1) JPH02504643A (es)
AT (1) ATE98630T1 (es)
AU (1) AU3772889A (es)
CA (1) CA1318615C (es)
DE (1) DE68911397T2 (es)
ES (1) ES2062061T3 (es)
WO (1) WO1989011876A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463080A (en) * 1992-08-27 1995-10-31 Bracco International B.V. 2,4,6-triiodo-1,3-benzenedicarboxylic acid compounds used as radiolabelling reagents
US5424402A (en) * 1993-10-18 1995-06-13 Board Of Trustees Of The University Of Kentucky Non-destructive method for radiolabelling biomolecules by halogenation
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5856106A (en) * 1995-11-01 1999-01-05 Biotransplant, Inc. Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
RU2218179C2 (ru) 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6129757A (en) * 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
ES2251204T3 (es) 1998-07-06 2006-04-16 Mgi Gp, Inc. Inhibidores de naaladasa utiles como compuestos y composiciones farmaceuticas.
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CA2670618C (en) * 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
CN102497884A (zh) * 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
US11384104B2 (en) * 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2808416A (en) * 1954-08-23 1957-10-01 Eastman Kodak Co Hydrazides of benzoic acid and derivatives thereof as antioxidants for fats and oils
US3809721A (en) * 1970-12-23 1974-05-07 Merck & Co Inc Substituted 2-aminomethyl-4,6-disubstituted phenols
DE2260933C3 (de) * 1972-12-08 1981-08-20 Schering Ag Berlin Und Bergkamen, 1000 Berlin Verfahren zur Herstellung von durch radioaktives Halogen markierten organischen Verbindungen
US3979506A (en) * 1974-10-11 1976-09-07 Pierce Chemical Company Radioactive compounds for labeling proteins
US4474746A (en) * 1980-08-08 1984-10-02 State University Of New York Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues
US4450149A (en) * 1981-06-15 1984-05-22 Research Corporation Radiohalogenation method
US4430319A (en) * 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
EP0203764B1 (en) * 1985-05-17 1993-03-24 Neorx Corporation Radiohalogenated small molecules for protein labeling
US4764598A (en) * 1985-08-22 1988-08-16 The United States Of America As Represented By The Department Of Energy Precursors to radiopharmaceutical agents for tissue imaging

Also Published As

Publication number Publication date
WO1989011876A1 (en) 1989-12-14
JPH02504643A (ja) 1990-12-27
CA1318615C (en) 1993-06-01
ATE98630T1 (de) 1994-01-15
AU3772889A (en) 1990-01-05
US4966999A (en) 1990-10-30
DE68911397T2 (de) 1994-05-26
DE68911397D1 (de) 1994-01-27
EP0348261B1 (en) 1993-12-15
EP0348261A1 (en) 1989-12-27

Similar Documents

Publication Publication Date Title
ES2062061T3 (es) Compuestos radiohalogenados para el marcaje especifico de sitio.
ES2175519T3 (es) Uso de derivados de acido7-(2-oxa-5,8-diazabiciclo(4,3,0)non-8-8-il)-quinoloncarboxilico y-naftiridoncarboxilico para la fabricacion de un medicanto para la terapia de infecciones por helicobacter pylori y las enfermedades gastroduodenales asociadas con ellas.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2039334T1 (es) Composiciones mejoradas de cemento combinado y portland.
ES2074055T3 (es) Derivados de amina de antibioticos de antraciclina.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
GT199900217A (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios.
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
AR025756A1 (es) Un compuesto de acido sustituido, composiciones y combinaciones farmaceuticas que lo comprenden y su uso para la preparacion de medicamentos
ES2094380T3 (es) Nuevos pirazolilpirazoles sustituidos, procedimientos para su preparacion, asi como compuestos intermedios, y su uso como herbicidas.
ES2065324T3 (es) N-(piridinil)-1h-indol-1-aminas, un procedimiento para su preparacion y su uso como medicamentos.
ES2091757T3 (es) Agonistas y agonistas parciales del neuropeptido y.
ES2061528T3 (es) Un procedimiento para preparar nuevos derivados de poliamina.
ES2013219T3 (es) Procedimiento para la conservacion de madera y materiales de madera.
ES2061559T3 (es) Triazolinonas substituidas.
ES2051862T3 (es) Un metodo para producir un medicamento que tiene un efecto catartico.
SV2003000766A (es) Procedimiento para la preparacion de imidazotriazinonas substituidas con sulfonamida ref. lea 34451-sv
ES2054732T3 (es) Un procedimiento para preparar un derivado peptidico.
ES2061456T3 (es) Compuestos de quinoxalina y preparacion y uso de los mismos.
ES2078959T3 (es) Procedimiento de preparacion de derivados del benzoil-3-benzofurano.
ES2074508T3 (es) Benzocicloalquilaminopiridinaminas y compuestos afines, un procedimiento e intermediarios para su preparacion y su uso como medicamentos.
AR048840A1 (es) Epitopes inductores de la muerte de las celulas t
ES8406500A1 (es) Procedimiento para la preparacion de derivados de beta-d-galactosa
ES2036238T3 (es) Derivados de hidroxietil-azolilo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 348261

Country of ref document: ES